Compare SUNS & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | AVXL |
|---|---|---|
| Founded | 2023 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 115.9M |
| IPO Year | 2024 | 2013 |
| Metric | SUNS | AVXL |
|---|---|---|
| Price | $6.96 | $1.26 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.25 | N/A |
| AVG Volume (30 Days) | 79.8K | ★ 1.2M |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | ★ 17.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $21,571,434.00 | N/A |
| Revenue This Year | $91.54 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | $12.43 | ★ N/A |
| Revenue Growth | ★ 102.96 | N/A |
| 52 Week Low | $5.77 | $1.13 |
| 52 Week High | $10.45 | $7.60 |
| Indicator | SUNS | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 27.79 |
| Support Level | $6.20 | $1.14 |
| Resistance Level | $7.90 | $1.60 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 80.00 | 14.89 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.